Post a Comment Print Share on Facebook
Featured Caser Aragonès Japón Contaminación LOréal

RELEASE: Bormioli Pharma launches its updated ESG Report. 45% sustainable materials in products sold

(Information sent by the signatory company).

- 3 reads.

RELEASE: Bormioli Pharma launches its updated ESG Report. 45% sustainable materials in products sold

(Information sent by the signatory company)

- Bormioli Pharma launches the 3rd edition of its ESG Report reaching 45% sustainable materials in products sold with its EcoPositive range

The company also confirms its commitment to a 30% reduction in Carbon Intensity and a 41% reduction in Water Extraction Intensity by 2030 compared to the 2021 baseline.

PARMA, Italy, April 23, 2024 /PRNewswire/ -- Bormioli Pharma, an international leader in pharmaceutical packaging and medical devices, today announced the third edition of its Sustainability Report.

This edition summarizes and consolidates the strong progress made by Bormioli Pharma in promoting sustainable growth in the communities in which the company lives and works, and highlights its strong commitment to supporting the pharmaceutical industry in its transition to environmentally friendly solutions. .

Of the main actions undertaken by the company during the year, the decision to proceed with external verification of the Report two years before legal obligations has been one of the most pioneering among the sector. In 2023, the ESG team and governance were also reinforced, which has led to the definition of solid processes included in its ESG Policy.

Regarding key sustainability targets, Bormioli Pharma confirmed its commitment to reduce carbon intensity by 30% and water extraction intensity by 41% by 2030 (compared to baseline 2021). The goal of increasing the proportion of sustainable materials[1] in the products sold continued to advance and has already achieved surprising results: the company is very close to the goal of 50% by 2025, reaching 45% in 2023 (15% compared to 2022 ).

“In 2023 we work vigorously to be an important driver of responsible growth, highlighting our role as a partner of the pharmaceutical industry in the development of increasingly widespread, effective and sustainable medical practices,” says Andrea Lodetti, CEO of Bormioli Pharma. "Among the initiatives launched during this journey, we have further expanded one of the largest sustainable packaging offerings available in the pharmaceutical industry, EcoPositive, a concrete action to support the EU's objectives on sustainable packaging."

Another pillar of Bormioli Pharma's ESG commitment is related to promoting a culture of Diversity and Inclusion throughout the organization with the goal of reaching 95% of employees trained in these topics by 2025.

Finally, the document highlights the objective of completing the evaluation of 90% of suppliers on the international EcoVadis platform by 2026.

The financial results obtained in 2023 - with an increase in revenue of 18% compared to the previous year - confirm the validity of Bormioli Pharma's strategic choices and reaffirm how it is possible to plan long-term development while still generating value for companies. people, the environment and society.

Bormioli Pharma is a world-renowned packaging company that offers complete solutions (bottles, closures, accessories) to the pharmaceutical industry. With more than 1,400 employees and 9 plants throughout Europe, the Group records annual sales of approximately 370 million euros.

[1] Sustainable materials include recycled glass, recycled plastic for the production of bottles and caps, bio-based materials for the production of packaging and materials from CO recovery.

Photo -

View original content: